Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries

American Journal of Pathology

Volumn 162, Issue 6, 2003, Pages 1881-1893

  Ferrara, Napoleone ^a   Frantz, Gretchen ^a   LeCouter, Jennifer ^a   Dillard Telm, Lisa ^a   Pham, Thinh ^a   Draksharapu, Aparna ^a   Giordano, Thomas ^b   Peale, Franklin ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; MESSENGER RNA; MITOGENIC AGENT; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM FUNCTION; ENDOCRINE GLAND; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LEYDIG CELL; OVARY CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

EID: 0038363403     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64322-2     Document Type: Article

References (50)

1. Bassett DL: The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle. Am J Anat 1943, 73:251-278
2. Zeleznik AJ, Schuler HM, Reichert Jr LE: Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology 1981, 109:356-362
3. Carr BR, MacDonald PC, Simpson ER: The role of lipoproteins in the regulation of progesterone secretion by the corpus luteum. Fertil Steril 1981, 38:303-311
4. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG: Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998, 78:1385-1394
5. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegend SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60
6. Goldziher JW, Green JA: The polycistic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962, 22:325-332
7. Yen, SSC: A contemporary overview. Reproductive Endocrinology, Surgery, and Technology. Edited by EY Adashi, JA Rock, Z Rosenwaks Philadelphia, Lippincott-Raven, 1996, pp 1117-1126
8. Dewailly D, Robert Y, Helin I, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, Fossati P: Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol (Oxf) 1964, 41:557-562
9. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A: A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001, 76: 326-331
10. Dunaif A, Thomas A: Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001, 52:401-419
11. Phillips HS, Hains J, Leung DW, Ferrara N: Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology 1990, 127:965-967
12. Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N, Zeleznik AJ: Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 1992, 131:254-260
13. Ferrara N, Chen H, Davis-Smyth T, Gerber, H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ, Schwall RH: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998, 4:336-340
14. Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O'Neill CA: Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999, 27:78-86
15. Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, Bicknell R: Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 2000, 141:995-1000
16. Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J, Ferin M: Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J Clin Endocrinol Metab 2001, 86:768-772
17. Ferrara N: Vascular endothelial growth factor: a key regulator of physiological angiogenesis. Vascular Morphogenesis in the Female Reproductive System. Edited by HG Augustin, L Iruela-Arispe, PAW Rogers, SK Smith. Boston, Birkhauser, 2001, pp 149-165
18. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller G-A, Peale F, Gurney A, Hillan KJ, Ferrara N: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001, 412:877-884
19. LeCouter J, Lin R, Ferrara N: Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002, 8:913-917
20. Joubert FJ, Strydom DJ: Snake venom. The amino acid sequence of protein A from Dendroaspis polylepis polylepis (black mamba) venom. H-S Z Physiol Chem 1980, 361:1787-1794
21. Aravind L, Koonin EV: A colipase fold in the carboxy-terminal domain of the Wnt antagonists - the Dickkopfs. Curr Biol 1998, 8:477-478
22. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C: Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362
23. Wechselberger C, Puglisi R, Engel E, Lepperdinger G, Boitani C, Kreil G: The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes. FEBS Lett 1999, 462:177-181
24. Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY: Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle. Mol Pharmacol 2001, 59:692-698
25. 33P-labeled riboprobes. Cell Vis 1994, 7:53-64
26. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale Jr FV, Shelton DL, Hebert CC: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000, 19:4046-4055
27. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789-1797
28. Clement PB: Histology of the ovary. Am J Surg Pathol 1987, 11:277-303
29. Corner GWJ: The histological dating of the human corpus luteum of menstruation. Am J Anat 1956, 9:377-401
30. Clement PB: Histology of the ovary. Histology for Pathologists, ed 2. Edited by SS Sternberg Philadelphia, Lippincott, 1997, pp 929-959
31. Sternberg WH: The morphology, androgenic function, hyperplasia and tumors of the ovarian hilus cells. Am J Pathol 1949, 25:493-521
32. Merrill JA: Ovarian hilus cells. Am J Obstet Gynecol 1959, 78:1258-1271
33. LeCouter J, Lin R, Frantz G, Tejada M, Peale F, Hillan KJ, Ferrara N: The endocrine gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA 2003, 100:2685-2690
34. Yamamoto S, Konishi I, Tsuruta Y, Nanbu K, Mandai M, Kuroda H, Matsushita K, Hamid AA, Yura Y, Mori T: Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 1997, 11: 371-381
35. Melchiorri D, Bruno V, Besong G, Ngomba RT, Cuomo L, De Blasi A, Copani A, Moschella C, Storto M, Nicoletti F, Lepperdinger G, Passarelli F: The mammalian homologue of the novel peptide Bv8 is expressed in the central nervous system and supports neuronal survival by activating the MAP kinase/P-3-kinase pathways. Eur J Neurosci 2001, 13:1694-1702
36. Cheng MY, Bullock CM, Li C, Lee AG, Bermak JC, Belluzzi J, Weaver DR, Leslie FM, Zhou QY: Prokineticin 2 transmits the behavioral circadian rhythm of the suprachiasmatic nucleus. Nature 2002, 417: 405-410
37. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999, 56:794-814
38. Tulandi T, Saleh A, Morris D, Jacobs HS, Payne NN, Tan SL: Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome. Fertil Steril 2000, 74:585-588
39. Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan SL, Campbell S, Jacobs HS: Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum Reprod 1998, 13:651-655
40. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol 1995, 146:157-165
41. Yen SSC: Polycystic ovary syndrome (hyperandrogenic chronic anovulation), Reproductive Endocrinology. Edited by SSC Yen, RB Jaffe, RL Barbieri, Philadelphia, W. B. Saunders, 1999, pp 436-78
42. Almahbobi G, Anderiesz C, Hutchinson P, McFarlane JR, Wood C, Trounson AO: Functional integrity of granulosa cells from polycystic ovaries. Clin Endocrinol 1996, 44:571-580
43. Cataldo NA, Dumesic DA, Goldsmith PC, Jaffe RB: Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relationship to apoptosis Hum Reprod 2000, 15: 1889-1997
44. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744
45. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1:193-202
46. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, Connolly DT, Robertson DM: Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994, 344:235-269
47. Engel T, Jewelewicz R, Dyrenfurth I, Speroff L, Vande Wiele RL: Ovarian hyperstimulation syndrome: report of one case with notes on pathogenesis and treatment. Am J Obstet Gynecol 1972, 112:1052-1057
48. Haning RJ, Strawn E, Nolten W: Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1985, 166:220-224
49. Kemmann E, Tavakoli F, Shelden RM, Jones JR: Induction of ovulation with menotropins in women with polycystic ovary syndrome. Am J Obstet Gynecol 1981, 141:58-64
50. Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T: The kallikreinkinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome. J Mol Endocrinol 1998, 20:363-374